1978-20-7

Usage

Uses

Used in Pharmaceutical Industry:
3,4-BIS(TRIFLUOROMETHYL)NITROBENZENE is used as a reactant for the synthetic preparation of 4,5-bis(trifluoromethyl)benzimidazole, which is an important intermediate in the development of pharmaceutical compounds. The benzimidazole core is a common structural motif found in many bioactive molecules, making 3,4-BIS(TRIFLUOROMETHYL)NITROBENZENE a valuable building block in the synthesis of potential therapeutic agents.
Used in Chemical Synthesis:
In the field of organic chemistry, 3,4-BIS(TRIFLUOROMETHYL)NITROBENZENE serves as a versatile intermediate for the synthesis of a wide range of organic compounds, including those with potential applications in various industries such as agriculture, materials science, and pharmaceuticals. Its unique structure allows for further functionalization and modification, making it a valuable asset in the development of new molecules with desired properties.

InChI:InChI=1/C8H3F6NO2/c9-7(10,11)5-2-1-4(15(16)17)3-6(5)8(12,13)14/h1-3H

Upstream product

• 433-95-4 1,2-bis(trifluoromethyl)benzene 
• 121-01-7 4-nitro-2-trifluoromethyl-aniline 
• 680-15-9 2,2-difluoro-2-(fluorosulfonyl)acetate 
• 400-75-9 1-iodo-4-nitro-2-(trifluoromethyl)benzene 
• 707-72-2 o-trifluoromethyl-α,α-dichlorotoluene 
• 610-27-5 4-nitrophthalic acid 
• 651-36-5 trichloromethyl-trifluoromethyl-benzene 
• 2741-57-3 o-dichloromethyltrichloromethylbenzene 

Downstream Products

• 1417658-11-7 N-(3,4-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide 
• 794-56-9 1-(trifluoroacetamido)-3,4-bis(trifluoromethyl)benzene 
• 2965-07-3 3,4-Bis(trifluoromethyl)aniline 
• 610-27-5 4-nitrophthalic acid 

Relevant academic research and scientific papers

Discovery of Potent Antiallergic Agents Based on ano-Aminopyridinyl Alkynyl Scaffold

Effective therapeutic agents are highly desired for immune-mediated allergic diseases. Herein, we report the design, synthesis, and structure-activity relationship of ano-aminopyridinyl alkyne series as novel orally bioavailable antiallergic agents, which

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.